|
|
|
|
|
Twitter
Giannis Mountzios ESMO21, EGFR, NSCLC, LCSM: 18/09/2021 22:25:01
|
|
|
|
Another trial from #ESMO21 reinforcing the concept of synergistic effect between EGFR-TKIs and Anti-angiogenic treatment in #EGFR positive #NSCLC The big question now is how to interpret this data in the osimertinib era , since there are no direct comparisons
@EGFRmNSCLC #LCSM
Read more
|
|
|
|
|
|
|
|
|
Twitter
Giannis Mountzios ESMO21, Immunotherapy, NSCLC: 19/09/2021 06:38:25
|
|
|
|
@OncoAlert #ESMO21 JAK mutations as drivers of #Immunotherapy resistance in advanced #NSCLC through loss of IFN-γ sensitivity abrogating the inflammatory cascade, elegantly presented by @CelineMascaux We need to better understand biology of IO resistance to develop new tt combos
Read more
|
|
|
|
|
|
|
|
|
Twitter
CancerNetwork®, Home of the Journal ONCOLOGY® NSCLC, WCLC21: 18/09/2021 17:15:06
|
|
|
|
Findings from a phase 2 trial indicate that the use of neoadjuvant osimertinib may hold promise in a population of patients with EGFR-mutated non–small cell lung cancer. #NSCLC #WCLC21 | @IASLC @collin_blakely
Read more
|
|
|
|
|
|
|
|
|
Twitter
Giannis Mountzios ESMO21, immunotherapy, NSCLC, LCSM, some: 19/09/2021 00:06:20
|
|
|
|
#ESMO21 Open questions on refinement of #immunotherapy in advanced #NSCLC by Dr Garon in educational session: Contra-indications of Immunotherapy, patient selection for mono therapy, duration of IO and efficacy in oncogene-driven tumors is discussed #LCSM #some
Read more
|
|
|
|
|
|
|
|
|
Twitter
Giannis Mountzios ESMO21, NSCLC: 18/09/2021 23:59:06
|
|
|
|
#ESMO21 Educational session on Immunotherapy challenges and unanswered questions in advanced #NSCLC by @NReguart a must-watch for every practicing oncologist
Read more
|
|
|
|
|
|
|
|
|
Twitter
Clinical OMICs NSCLC: 18/09/2021 20:25:02
|
|
|
|
Researchers from @MDAndersonNews say that grouping epidermal growth factor receptor (EGFR) mutations by structure and function can help to better match non-small cell lung cancer patients to the most promising treatments. Learn more: https://t.co/XCVIgp0wux #NSCLC
Read more
|
|
|
|
|
|
|
|
|
Twitter
Giannis Mountzios ESMO21, immunotherapy, NSCLC, LCSM, some: 18/09/2021 19:03:51
|
|
|
|
@OncoAlert just out in @ESMO_Open to coincide with #ESMO21 a German-Greek collaboration on the role of Advanced Lung Cancer Inflammation Index (ALI) in predicting #immunotherapy efficacy wt or wt chemo in advanced #NSCLC (thread follows) : (1/8)
#LCSM #some @myESMO
Read more
|
|
|
|
|
|
|
|
|
Twitter
MedPub MedicalNews, MedTwitter, MedEd: 18/09/2021 16:53:07
|
|
|
|
Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC
For more up-to-date medical headlines, visit https://t.co/8ugyCPRjur
#MedicalNews #MedTwitter #MedEd
Read more
|
|
|
|
|
|
|
|
|
Twitter
OncLive.com ESMO2021, lcsm: 18/09/2021 16:55:15
|
|
|
|
Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC @erasmusmcintl @myESMO #ESMO2021 #lcsm https://t.co/q53TXh5anV
Read more
|
|
|
|
|
|
|
|
|
Twitter
Oncology Publishers Feed Oncology, MedTwitter, MedEd: 18/09/2021 16:51:23
|
|
|
|
Daily Poziotinib Shows Promise in Untreated HER2 Exon 20–Mutant NSCLC
More medical news at https://t.co/Z2xEnRpr3X
#Oncology #MedTwitter #MedEd
Read more
|
|
|
|
|
|
|
|
|
Twitter
Pharmacutical Daily : 18/09/2021 17:22:07
|
|
|
|
Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021
Read more
|
|
|
|
|
|
|
|
|
Twitter
Vladmir C. Cordeiro de Lima, MD, PhD : 18/09/2021 16:12:07
|
|
|
|
GEMSTONE-301 confirms benefit of of ICI folllowing CRT in stage III NSCLC, although medians were shorter. Signal of improved OS. Sequential CRT allowed and also benefited of IO. EGFR, ALK and ROS1 mutants excluded. @ESMO21@ GBOTalerta
Read more
|
|
|
|
|
|
|
|
|
Twitter
Stephen V Liu ESMO21, EGFR, ALK: 18/09/2021 16:49:24
|
|
|
|
#ESMO21 Retrospective analysis of the use of durvalumab after chemoradiation (PACIFIC) in patients with unresectable NSCLC harboring a driver alteration. In PACIFIC, the #EGFR and #ALK subset did not seem to derive as much benefit & TKI post IO is more toxic. Very relevant data.
Read more
|
|
|
|
|
|
|
|
|
Twitter
Covalent Modifiers : 18/09/2021 20:37:03
|
|
|
|
Structure-based classification predicts drug response in EGFR-mutant NSCLC https://t.co/2pjDnd6i8A
Read more
|
|
|
|
|
|
|
|
|
Twitter
Medscape WCLC21: 18/09/2021 22:15:00
|
|
|
|
New data on the use of immunotherapy in early stages of NSCLC have sparked a debate on which patients benefit most.
Read more
|
|
|
|
|
|
|
|
|
Twitter
cadranel jacques : 18/09/2021 16:30:19
|
|
|
|
No place for IO in oncogenic driven NSCLC in no/low smoking exposure such as EGFR- or fusion although their prognosis is clearly not good. Here in the context of durva consolidation post CT-RT in IIIA-IIIB NSCLC. Important for the practice. KRAS/MET/BRAF different. 👏M Rudiavets.
Read more
|
|
|
|
|
|
|
|
|
Twitter
Dr. Estela Rodriguez ESMO21, lcsm: 18/09/2021 23:10:19
|
|
|
|
#ESMO21 Ph2 WJOG9717L: Osimertinib + Bev for +EGFR NSCLC. Another negative trial for Osimertinib + VEGF w no improvement in PFS--> Still looking for the best VEGF partner for Osimertinib, ?benefit in ever-smokers.
#lcsm @EGFResister @myESMO @oncoAlert
Read more
|
|
|
|
|
|
|
|
|
Twitter
Antonio Passaro, MD PhD ESMO21, LCSM: 18/09/2021 16:24:52
|
|
|
|
#ESMO21 #LCSM
Dr Riudavets Melia discussed the role of durva in pts w/ stage III non-resect NSCLC w/ driver alterations (EGFR, BRAF, KRAS, ALK & ROS1)
Retrosp study (43 w/ diver / 323 pts)
mPFS 17.5
mOS 47.0
No diff in mPFS accorting to PD-L1 status
No clear data from my side
Read more
|
|
|
|
|
|
|
|
|
Twitter
Stephen V Liu ESMO21, EGFR, ALK, ROS1, LCSM: 18/09/2021 16:15:52
|
|
|
|
#ESMO21 Enrolled 368 pts with unresectable NSCLC after chemoradiation with randomization to sugemalimab. Distinct from PACIFIC: included sequential CRT not just concurrent, excluded #EGFR #ALK #ROS1, treatment was 2y not 1y, and more squamous histology. #LCSM @myESMO
Read more
|
|
|
|
|
|
|
|
|
Twitter
OncLive.com lcsm: 19/09/2021 03:00:09
|
|
|
|
WATCH: @collin_blakely, of @UCSFCancer, discusses the design of an ongoing phase 2 trial examining osimertinib in resectable EGFR-mutant non–small cell lung cancer. #lcsm
Read more
|
|
|
|
|
|
|
|
|
Twitter
deniztural : 19/09/2021 06:00:53
|
|
|
|
FDA Grants Accelerated Approval to Mobocertinib for Patients With Metastatic NSCLC and EGFR Exon 20 Insertion Mutations - The ASCO Post
Read more
|
|
|
|
|
|
|
|
|
Twitter
The ASCO Post lcsm, oncology, cancer: 18/09/2021 16:11:00
|
|
|
|
In the Clinic: Amivantamab-vmjw for Previously Treated Advanced NSCLC With EGFR Mutation
Read more
|
|
|
|
|
